No Fluff. Just Sources.
HomeArticles › Wegovy HD 7.2mg: The Data Behind the Strongest Semaglutide Dose
DATA7 min read

Wegovy HD 7.2mg: The Data Behind the Strongest Semaglutide Dose

Semaglutide 7.2mg was approved May 13, 2026 under accelerated review. Here's every data point from the STEP UP trial, sourced and contextualized.

Drug: Semaglutide 7.2mg (Wegovy HD) — once-weekly injection

Trial: STEP UP (NCT05646706) — 72 weeks

Mean weight loss: 20.7%

≥25% weight loss: ~33% of participants

Review time: 54 days (CNPV pilot)

STEP UP: The Numbers

Metric7.2mg2.4mg (reference)
Mean weight loss20.7%~15%
≥20% weight loss~50%~32%
≥25% weight loss~33%~12%

At 20.7%, Wegovy HD matches tirzepatide 15mg (20.9% in SURMOUNT-1) for the first time — semaglutide is no longer the lower-efficacy option at maximum doses.

Safety Signal: Altered Skin Sensation

One new finding at 7.2mg: increased reports of sensitivity, pain, or burning skin sensation. The FDA is investigating further. Symptoms generally resolve with dose reduction. GI side effects (nausea, diarrhea, vomiting) remain consistent with lower doses.1

Boxed warning: thyroid C-cell tumor risk. Contraindicated with MTC history or MEN2 syndrome.

Liv Body · from $199/mo

Explore GLP-1 Options →

Compounded medications are not FDA-approved. Paid link

Market Context

Wegovy HD arrives alongside oral Wegovy ($149/month, launched January 2026) and amid the FDA's 503B Bulks List proposal. The semaglutide product line now spans three formulations — pill, standard injection, and high-dose injection — giving providers and patients more options than any other GLP-1.

Oak Longevity Compounded

$130/mo sema

Check Eligibility → Paid link

Compounded medications are not FDA-approved.

Sesame Care Brand-Name

brand-name Rx

Check Eligibility → Paid link

The Source Summary

Wegovy HD at 7.2mg closes the gap with tirzepatide, delivering 20.7% weight loss with one in three patients exceeding 25%. The 54-day approval signals urgency from regulators. Current options remain strong while HD ramps to availability mid-2026.

Sources

  1. Drug Topics. "FDA Approves New Higher Dose of Semaglutide, Wegovy HD." May 13, 2026.
  2. STEP UP trial (NCT05646706).
  3. SURMOUNT-1 trial, tirzepatide 15mg, for comparison.

Related